Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions

Cancer Cytopathology

Volumn 122, Issue 9, 2014, Pages 685-693

  Cappellesso, Rocco ^a   Tinazzi, Andrea ^a   Giurici, Thomas ^a   Simonato, Francesca ^a   Guzzardo, Vincenza ^a   Ventura, Laura ^a   Crescenzi, Marika ^b   Chiarelli, Silvia ^a   Fassina, Ambrogio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

exosomes; malignant effusions; microRNA 21 (MIR 21); ovarian carcinoma; programmed cell death 4 (PDCD4)

Indexed keywords

MEMBRANE RECEPTOR; MICRORNA 21; PROGRAMMED CELL DEATH 4; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; MICRORNA; MIRN21 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; PRIMER DNA; RNA BINDING PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTADENOMA; DISEASE ACTIVITY; EFFUSION; EXOSOME; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OVARIAN SEROUS CARCINOMA; OVARY CARCINOMA; PERITONEAL EFFUSION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ASCITES FLUID; GENETICS; MALIGNANT EFFUSIONS; METABOLISM; MICRORNA-21 (MIR-21); NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; PROGRAMMED CELL DEATH 4 (PDCD4);

EXOSOMES; MALIGNANT EFFUSIONS; MICRORNA-21 (MIR-21); OVARIAN CARCINOMA; PROGRAMMED CELL DEATH 4 (PDCD4);

AGED; APOPTOSIS REGULATORY PROTEINS; ASCITIC FLUID; BASE SEQUENCE; DNA PRIMERS; EXOSOMES; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS;

EID: 84908494725     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21442     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. Cannistra SA,. Cancer of the ovary. N Engl J Med. 2004; 351: 2519-2529.
3. Vergote I, Trope CG, Amant F, et al,; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363: 943-953.
4. Vergote I, Trope CG, Amant F, Ehlen T, Reed NS, Casado A,. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol. 2011; 29: 4076-4078.
5. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ,. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20: 1248-1259.
6. Trope CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H,. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV? Eur J Cancer. 2012; 48: 2146-2154.
7. Cmarik JL, Min H, Hegamyer G, et al., Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci U S A. 1999; 96: 14037-14042.
8. Mudduluru G, Medved F, Grobholz R, et al., Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer. 2007; 110: 1697-1707.
9. Yang HS, Jansen AP, Nair R, et al., A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation. Oncogene. 2001; 20: 669-676.
10. Yang HS, Jansen AP, Komar AA, et al., The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol. 2003; 23: 26-37.
11. Fassan M, Cagol M, Pennelli G, et al., Programmed cell death 4 protein in esophageal cancer. Oncol Rep. 2010; 24: 135-139.
12. Pennelli G, Fassan M, Mian C, et al., PDCD4 expression in thyroid neoplasia. Virchows Arch. 2013; 462: 95-100.
13. Fassan M, Pizzi M, Giacomelli L, et al., PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis. Virchows Arch. 2011; 458: 413-419.
14. Wang X, Wei Z, Gao F, et al., Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma. Anticancer Res. 2008; 28: 2991-2996.
15. Wei NA, Liu SS, Leung TH, et al., Loss of programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer. Mol Cancer. 2009; 8: 70.
16. Kharaziha P, Ceder S, Li Q, Panaretakis T,. Tumor cell-derived exosomes: a message in a bottle. Biochim Biophys Acta. 2012; 1826: 103-111.
17. Martins VR, Dias MS, Hainaut P,. Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol. 2013; 25: 66-75.
18. Zhang HG, Grizzle WE,. Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol. 2014; 184: 28-41.
19. Tavassoli FA, Devilee P, eds,. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
20. Rosato A, Menin C, Boldrin D, et al., Survivin expression impacts prognostically on NSCLC but not SCLC. Lung Cancer. 2013; 79: 180-186.
21. Manni S, Brancalion A, Mandato E, et al., Protein kinase CK2 inhibition down modulates the NF-kappaB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS One. 2013; 8: e75280.
22. Fassina A, Cappellesso R, Guzzardo V, et al., Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol. 2012; 25: 86-99.
23. Fassina A, Cappellesso R, Fassan M,. Classification of nonsmall cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling. Chest. 2011; 140: 1305-1311.
24. Fassina A, Marino F, Siri M, et al., The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest. 2012; 92: 1574-1582.
25. Simonato F, Ventura L, Sartori N, et al., Detection of microRNAs in archival cytology urine smears. PLoS One. 2013; 8: e57490.
26. Fassina A, Cappellesso R, Simonato F, et al., A 4-microRNA signature can discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology smears. Cancer (Cancer Cytopathol). 2014; 122: 274-281.
27. Wei ZT, Zhang X, Wang XY, et al., PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci. 2009; 100: 1408-1413.
28. Zhang X, Wang X, Song X, et al., Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo. Cancer Sci. 2010; 101: 2163-2170.
29. Chan JK, Blansit K, Kiet T, et al., The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol. 2014; 132: 739-744.
30. Wei N, Liu SS, Chan KK, Ngan HY,. Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. PLoS One. 2012; 7: e30311.
31. Nam EJ, Yoon H, Kim SW, et al., MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008; 14: 2690-2695.
32. Liu S, Fang Y, Shen H, Xu W, Li H,. Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis. Acta Biochim Biophys Sin (Shanghai). 2013; 45: 756-762.
33. Kogure T, Lin WL, Yan IK, Braconi C, Patel T,. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology. 2011; 54: 1237-1248.
34. Ohshima K, Inoue K, Fujiwara A, et al., Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One. 2010; 5: e13247.
35. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al., Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A. 2010; 107: 6328-6333.
36. Zhang Y, Liu D, Chen X, et al., Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 2010; 39: 133-144.
37. Taylor DD, Gercel-Taylor C,. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008; 110: 13-21.